Teza Capital Management LLC Invests $710,000 in Charles River Laboratories International, Inc. (NYSE:CRL)

Teza Capital Management LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 3,847 shares of the medical research company's stock, valued at approximately $710,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Veracity Capital LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $589,000. Allspring Global Investments Holdings LLC grew its position in shares of Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after purchasing an additional 47,221 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Charles River Laboratories International by 46.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company's stock valued at $987,000 after purchasing an additional 1,679 shares during the period. Boston Trust Walden Corp grew its position in shares of Charles River Laboratories International by 4.3% in the fourth quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company's stock valued at $37,748,000 after purchasing an additional 8,338 shares during the period. Finally, E. Ohman J or Asset Management AB grew its position in shares of Charles River Laboratories International by 225.0% in the fourth quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company's stock valued at $480,000 after purchasing an additional 1,800 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $141.36 on Tuesday. The company has a market capitalization of $6.94 billion, a price-to-earnings ratio of 942.40, a PEG ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The business has a 50-day moving average of $134.84 and a 200-day moving average of $164.49.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same quarter in the prior year, the business posted $2.27 earnings per share. Charles River Laboratories International's revenue for the quarter was down 2.7% on a year-over-year basis. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on CRL shares. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a research report on Monday, March 3rd. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. The Goldman Sachs Group downgraded Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price target for the company from $190.00 to $170.00 in a research report on Friday, March 21st. Mizuho lowered their price target on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. Finally, JPMorgan Chase & Co. lowered their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International currently has a consensus rating of "Hold" and an average price target of $172.31.

Insider Buying and Selling at Charles River Laboratories International

In related news, COO Birgit Girshick purchased 1,514 shares of the company's stock in a transaction dated Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares of the company's stock, valued at $9,064,198.54. This trade represents a 2.83% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,040 shares of company stock worth $807,407 over the last quarter. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.